ICMJE DISCLOSURE FORM

Date:March, 30 th , 2022
Your Name:Zheng Li
Manuscript Title: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated
white blood cell clusters in non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

Date:March, 30 th , 2022
Your Name:Liwen Fan
Manuscript Title: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated
white blood cell clusters in non-small cell lung cancer
Manuscript number (if known):

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

Date:March, 30 th , 2022
/our Name:Yuxu Niu
Manuscript Title: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated
white blood cell clusters in non-small cell lung cancer
Manuscript number (if known):

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

Date: March, 30 th , 2022
Your Name: Xuelin Zhang
Manuscript Title: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated
white blood cell clusters in non-small cell lung cancer
Manuscript number (if known):

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

Date:N	larch, 30 th , 2022
Your Name: _	Bin Wang
Manuscript Ti	tle: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated
white blood c	ell clusters in non-small cell lung cancer
Manuscript no	umber (if known):

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

1 ----

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

Date:March, 30 th , 2022
Your Name:Chunji Chen
Manuscript Title: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated
white blood cell clusters in non-small cell lung cancer
Manuscript number (if known):

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

Date:March, 30 th , 2022
Your Name:Ning Qi
Manuscript Title: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated
white blood cell clusters in non-small cell lung cancer
Manuscript number (if known):

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

Yo Ma wh	Date:March, 30 th , 2022 Your Name:Daisy Dandan Wang Manuscript Title: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated white blood cell clusters in non-small cell lung cancer Manuscript number (if known):				
rel pa to	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.				
	e following questions apply nuscript only.	to the author's relationship	ps/activities/interests as they relate to the <u>current</u>		
to me	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		needed) Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone			
		Time frame: past	36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).				
ß	Royalties or licenses	_XNone			
4	Consulting fees	_XNone			
5	Payment or honoraria for lectures, presentations,	XNone			

speakers bureaus, manuscript writing or

	advectional avents		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	Cytelligen, San Diego, CA, USA	technical support.
			employee

Daisy Dandan Wang is from Cytelligen, San Diego and reports that this research has received technical suppor
from Cytelligen, San Diego, CA, USA

Please place an "X" next to the following statement to indicate your agreement:

	te:March, 30 th , 2022				
Your Name:Peter Ping Lin					
	Manuscript Title: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated white blood cell clusters in non-small cell lung cancer				
In rel pa to rel Th ma	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,				
the	the time frame for disclosure is the past 36 months.				
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate none (add rows as	institution)		
		needed)			
		Time frame: Since the initia	l planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone			
		Time frame: past	36 months		
2	Grants or contracts from				
	any entity (if not indicated in item #1 above).				
3	Royalties or licenses	_XNone			
	Companie of the companie	V. Nama			
4	Consulting fees	_XNone			
5	Payment or honoraria for	XNone			

lectures, presentations, speakers bureaus,

	manuscript writing or educational events		
6	Payment for expert	_XNone	
	testimony		
7	Comment for attending	V Nove	
/	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	Cytelligen , San Diego, CA, USA	technical support.
			employee

Peter Ping Lin is from Cytelligen, San Diego and reports that this research has received technical support from Cytelligen, San Diego, CA, USA.

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>March, 30^{tn}, 2022</u>
Your Name:Dongfang Tang
Manuscript Title: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated
white blood cell clusters in non-small cell lung cancer
Manuscript number (if known):

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	XNone	
	manuscript writing or educational events		
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement:

Date:M	arch, 30 th , 2022
Your Name: _	Wen Gao
Manuscript Ti	tle: _Analysis of the prognostic role and biological characteristics of circulating tumor-cell-associated
white blood c	ell clusters in non-small cell lung cancer
Manuscript nu	umber (if known):

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This research was supported by Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113). And Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	_XNone		
4	Consulting fees	_XNone		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports the funding from Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (Project SHDC12018113), and Shanghai Hospital Clinical Research Cultivation Project (SHDC12019X11).

Please place an "X" next to the following statement to indicate your agreement: